EDITORIAL

974  How to identify early complications in patients undergoing distal gastrectomy?
Tropeano G, Chiarello MM, Fico V, Brisinda G

982  Quality assessment of surgery for colorectal cancer: Where do we stand?
Morarasu S, Livadaru C, Dimofte GM

988  Emerging molecules, tools, technology, and future of surgical knife in gastroenterology
Kumar A, Goyal A

999  Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions
Dilek ON, Arslan Kahraman DI, Kahraman G

1008  Relationship between Helicobacter pylori infection and colorectal polyp/colorectal cancer
Liu Y, Yang DQ, Jiang JN, Jiao Y

MINIREVIEWS

1017  Near-infrared cholangiography with intragallbladder indocyanine green injection in minimally invasive cholecystectomy

1030  Blastosmas of the digestive system in adults: A review

ORIGINAL ARTICLE

Retrospective Study

1043  Single-center retrospective study of the diagnostic value of double-balloon enteroscopy in Meckel’s diverticulum with bleeding

1055  Prognostic value of a nomogram model for postoperative liver metastasis of colon cancer
Cheng DX, Xu KD, Liu HB, Liu Y

1066  Computer-assisted three-dimensional individualized extreme liver resection for hepatoblastoma in proximity to the major liver vasculature

1078  Research on the prognostic value of adjusting intraperitoneal three-dimensional quality evaluation mode in laparoscopic cholecystectomy patients
Zhou Y, Chen ZQ
## Contents

### Construction of a predictive model for acute liver failure after hepatectomy based on neutrophil-to-lymphocyte ratio and albumin-bilirubin score

1087  
Li XP, Bao ZT, Wang L, Zhang CY, Yang W

### Predicting short-term thromboembolic risk following Roux-en-Y gastric bypass using supervised machine learning

1097  

### Comparative analysis of two digestive tract reconstruction methods in total laparoscopic radical total gastrectomy

1109  

### Incidence of surgical site infection in minimally invasive colorectal surgery

1121  
Ni LT, Zhao R, Ye YR, Ouyang YM, Chen X

### Observational Study

1130  
Burden of gallstone disease in the United States population: Prepandemic rates and trends

Unalp-Arida A, Ruhl CE

### Prospective Study

1149  
Kuicolog-yu enema decoction retains traditional Chinese medicine enema attenuates inflammatory response ulcerative colitis through TLR4/NF-κB signaling pathway

Han L, Tong K, Fang XL, Xu JX, Mao XY, Li M

### SYSTEMATIC REVIEWS

1155  
Quality-adjusted life years and surgical waiting list: Systematic review of the literature


### META-ANALYSIS

1165  
Impact of different anastomosis methods on post-recurrence after intestinal resection for Crohn's disease: A meta-analysis

Wang ZZ, Zhao CH, Shen H, Dai GP

### CASE REPORT

1176  
Suspected coexistence of perianal necrotizing sweet syndrome in chronic myelomonocytic leukemia: A case report

Yu KQ, Li HX, Wu J

1184  
Successful splenic artery embolization in a patient with Behçet's syndrome-associated splenic rupture: A case report

Zhu GZ, Ji DH

1189  
Sercoral perforation of the cecum: A case report

Yu HC, Pu TW, Kang JC, Chen CY, Hu JM, Su RY
World Journal of Gastrointestinal Surgery

Monthly Volume 16 Number 4 April 27, 2024

Contents

1195  Percutaneous transhepatic stenting for acute superior mesenteric vein stenosis after pancreaticoduodenectomy with portal vein reconstruction: A case report

1203  Endoscopic treatment of bleeding gastric ulcer causing gastric wall necrosis: A case report
Li WF, Gao RY, Xu JW, Yu XQ

1208  Intermittent melena and refractory anemia due to jejunal cavernous lymphangioma: A case report
Liu KR, Zhang S, Chen WR, Huang YX, Li XG

LETTER TO THE EDITOR

1215  New frontiers in ectopic pancreatic tissue management
Covantsev S
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Surgery, Arunachalam Rathnaswami, FACS, MBBS, MS, MNAMS, MCh, Ex-Professor and Head, Department of Surgical Gastroenterology, SRM Medical College Hospital and Research Institute SRMIST, Kattankulathur, Chennai, TamilNadu 603203, India. arunarathna@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Surgery (WJGS, World J Gastrointest Surg) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, etc.

INDEXING/ABSTRACTING
The WJGS is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGS as 2.0; IF without journal self cites: 1.9; 5-year IF: 2.2; Journal Citation Indicator: 0.52; Ranking: 113 among 212 journals in surgery; Quartile category: Q3; Ranking: 81 among 93 journals in gastroenterology and hepatology; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Zi-Hang Xu; Production Department Director: Xiang Le; Cover Editor: Jia-Ru Fan.
Relationship between *Helicobacter pylori* infection and colorectal polyp/colorectal cancer

Ying Liu, Ding-Quan Yang, Jun-Nan Jiang, Yan Jiao

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report’s scientific quality classification**
- Grade A (Excellent): 0
- Grade B (Very good): B, B
- Grade C (Good): 0
- Grade D (Fair): 0
- Grade E (Poor): 0

**P-Reviewer:** Bordin DS, Russia; Cassell III AK, Liberia

**Received:** January 10, 2024

**Peer-review started:** January 10, 2024

**First decision:** January 27, 2024

**Revised:** February 1, 2024

**Accepted:** March 13, 2024

**Article in press:** March 13, 2024

**Published online:** April 27, 2024

**Ying Liu,** Department of General Surgery, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun 130021, Jilin Province, China

**Ding-Quan Yang,** Jun-Nan Jiang, Department of Gastrointestinal and Colorectal Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China

**Yan Jiao,** Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China

**Corresponding author:** Yan Jiao, MD, PhD, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com

**Abstract**

*Helicobacter pylori* (*H. pylori*) plays an important role in the development of gastric cancer, although its association to colorectal polyp (CP) or colorectal cancer (CRC) is unknown. In this issue of *World Journal of Gastrointestinal Surgery*, Zhang et al investigated the risk factors for *H. pylori* infection after colon polyp resection. Importantly, the researchers used R software to create a prediction model for *H. pylori* infection based on their findings. This editorial gives an overview of the association between *H. pylori* and CP/CRC, including the clinical significance of *H. pylori* as an independent risk factor for CP/CRC, the underlying processes of *H. pylori*-associated carcinogenesis, and the possible risk factors and identification of *H. pylori*.

**Key Words:** *Helicobacter pylori*; Colorectal polyp; Colorectal cancer; Risk factor

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** *Helicobacter pylori* (*H. pylori*) infection is a significant risk factor for colorectal adenomatous polyp (CAP) or colorectal cancer (CRC), and it may contribute to the development of CRC via an inflammatory response, gastrin stimulation, intestinal flora modulation, and virulence factor invasion. In contrast, the diagnosis of CAP may independently predict the probability of *H. pylori* infection after colon polyp removal.
INTRODUCTION

*Helicobacter pylori* (H. pylori) is a microaerophilic, gram-negative bacteria that lives mostly in the stomach and duodenum of humans. It spreads to individuals by a variety of routes, including oral-oral, fecal-oral, and gastro-oral pathways[1]. Because to *H. pylori*’s various transmission channels, growing medication resistance, poor eradication rate, and insufficient treatment duration, 43.1 percent of the world population was infected from 2011 to 2022[2]. In impoverished nations, the *H. pylori* infection rate approached 70%, while infection rates in affluent countries varied from 25% to 50%[3]. Although most people with *H. pylori* infection are asymptomatic, long-term infection may cause chronic gastritis and is linked to a variety of non-gastric ailments, including atherosclerosis[4], type 2 diabetes[5], anemia[6], osteoporosis[7], and some immune-related disorders[8]. Furthermore, 1%-3% of those infected with *H. pylori* develop gastric cancer[9], and *H. pylori* infection is also strongly related with mucosa-associated lymphoid tissue lymphoma[10] and colorectal cancer (CRC)[11]. As a result, the World Health Organization’s International Cancer Research Centre designated *H. pylori* as a Class I biological carcinogen[12]. In conclusion, screening and eradication of *H. pylori* is an important primary preventative method for tumorigenesis[13].

In recent decades, the connection between *H. pylori* and colorectal polyph (CP) or CRC has sparked attention. And, there is accumulating clinical and basic experiment evidence indicating that *H. pylori* infection is a risk factor for CP/CRC and promotes the development of CRC. In this paper, two researchers (DQ-Y and Y-L) conducted independent literature searches using PubMed, Embase, and Cochrane Library databases to obtain more comprehensive literature data. The search was conducted from inception to December 2023, with search keywords including “Helicobacter pylori”, “*H. pylori*”, “Helicobacter pylori infection”, “*H. pylori* infection”, “colorectal polyp”, “CP”, “colorectal adenomatous polypla”, “CAP”, “colorectal adenoma”, “colorectal neoplasm”, “colorectal neoplasia”, “colorectal cancer”, “colorectal carcinoma”, “CRC”, and “colorectal tumor”. Additionally, manual searches of the reference lists of the obtained articles were conducted to avoid any omission of studies. Further, we investigate the link between *H. pylori* and CP/CRC, as well as the possible pathogenic processes involved.

THE ASSOCIATION BETWEEN H. PYLORI AND CP/CRC

Several case-control and retrospective cohort studies have shown a substantial link between *H. pylori* infection and the prevalence of CP/CRC[14-17]. Similarly, cross-sectional studies conducted in various areas and nations consistently shown that *H. pylori* infection was an independent risk factor for CP, especially colorectal adenomatous polyph (CAP)[18-21]. Boustany et al[22] reported the first findings from a large population-based analysis of 47714750 people, establishing an independent link between a history of *H. pylori* infection and the risk of CRC. A large-scale meta-analysis of 48 studies found that both CAP and CRC were linked to *H. pylori* infection and an increased risk of CRC. A prospective European multi-center investigation found that serum antibodies to *H. pylori* protein C and cytotoxin-associated gene A were linked to an elevated risk of CRC[23]. Yang et al[24] used a fixed-effects model to analyze 27 studies and discovered that different study methods, including case-control studies [odds ratio (OR) = 1.26, 95% confidence interval (95%CI): 1.16-1.36], cross-sectional studies (OR = 1.92, 95%CI: 1.17-3.16), and multiple detection methods (OR = 2.63, 95%CI: 1.09-6.31), all supported the strong link between *H. pylori* infection and an increased risk of CRC. A prospective European multi-center investigation found that serum antibodies to *H. pylori* protein C and cytotoxin-associated gene A were linked to an elevated risk of CRC[23]. *H. pylori* infection in patients with atrophic gastritis[26], intestinal metaplasia[27], diabetes[28], and metabolic syndrome[29] may enhance the risk of CAP. Further-more, as demonstrated in Table 1, *H. pylori* infection is linked to pathological clinical characteristics such as the size, number, location, and pathological type of CAP.

Individuals with present or past *H. pylori* infection have a 30% to 50% higher risk of developing CRC[30]. *H. pylori* infection was discovered as a predictive factor for the construction of the CAP-risk model, which has shown excellent clinical relevance in prospective cohort studies[31]. Triple treatment coupled with long-term use of proton pump inhibitors may lower the incidence of CAP caused by *H. pylori* infection[32], and *H. pylori* eradication before to surgery may become a novel immunotherapy method for CRC[33]. In contrast, if *H. pylori* is not adequately treated and continues, it might considerably increase the recurrence risk of CAP[34-36].

However, several clinical research did not find a substantial link between *H. pylori* and CP/CRC[37-39]. We take into account the criteria for positive *H. pylori* infection, *H. pylori* diagnostic methods, the interference of *H. pylori*-related diseases[26], incomplete colonoscopy, sample size and age[40,41], as well as ethnic[30,41] and regional environmental differences, all of which may lead to inconsistent results.

Zhang et al[42] performed thorough scientific research in this issue of World Journal of Gastrointestinal Surgery and proposed a novel route for researching the association between *H. pylori* and CP. The research found that age, body mass index (BMI), and CAP were independent predictors of *H. pylori* infection after post-colon polyph resection. In addition, the research used R software to create a column-line graph prediction model. The model has been demonstrated to have strong calibration, discrimination, and prediction abilities in predicting *H. pylori* risk by calculating calibration curves,
Table 1 The correlation between Helicobacter pylori infection and the clinicopathologic characteristics of colorectal polyp

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Variables related to H. pylori infection</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyp size (diameter)</td>
<td>&gt; 1.0 cm</td>
<td>Positive [14,93,95,96]</td>
</tr>
<tr>
<td>Polyp/adenomatous polyp number</td>
<td>&gt; 1.0</td>
<td>Negative [93]</td>
</tr>
<tr>
<td>Pathological type</td>
<td>Adenoma (all)</td>
<td>Positive [19-21,23,26,27,35,97,98,100-106]</td>
</tr>
<tr>
<td></td>
<td>Tubular adenoma</td>
<td>Positive [54,107]</td>
</tr>
<tr>
<td></td>
<td>Villous adenoma</td>
<td>Positive [14,93,96,107]</td>
</tr>
<tr>
<td></td>
<td>Tubular villous adenoma</td>
<td>Positive [14,34]</td>
</tr>
<tr>
<td></td>
<td>Hyperplastic polyp</td>
<td>Positive [36,96,103]</td>
</tr>
<tr>
<td></td>
<td>Serrated polyp</td>
<td>Positive [108]</td>
</tr>
<tr>
<td>Adenomatous polyp stage</td>
<td>Advanced adenoma</td>
<td>Positive [17,23,93,96,103,105]</td>
</tr>
<tr>
<td>Distribution of adenomatous polyp</td>
<td>Proximal</td>
<td>Positive [17,39]</td>
</tr>
</tbody>
</table>

H. pylori: Helicobacter pylori.

receiver operating characteristic curves, and decision curve analysis curves, as well as validating the model validation cohort. This prediction approach might aid in the early detection of H. pylori infection.

POTENTIAL CARCINOGENIC EFFECT OF H. PYLORI ON CRC

Impact of H. pylori-related inflammation on CRC

H. pylori is a major immunostimulant. Ralser et al.[11] discovered that in the Apc mutant mouse model, H. pylori infection recruited CD3+ T cells within the colon tissue epithelium, upregulated CD8+ T cells, and caused Treg cell loss and differentiation into potentially pathogenic Foxp3+ IL-17+ T cells[43], resulting in a specific pro-inflammatory immune response. Furthermore, the research found that H. pylori might activate the STAT3 cancer pathway in colon cells, further blocking Treg cell infiltration[44], which was followed by elevated Ki67 expression and reduced intestinal barrier marker PAS[11]. This research also provides the first direct evidence of a causal link between H. pylori infection and CRC. Furthermore, H. pylori may produce chronic gastritis, which exacerbates the systemic inflammatory response[45]. Inflammation has been linked to an increased risk of CRC, and long-term usage of aspirin as an anti-inflammatory medication may help prevent CRC[46]. Future research in CRC will concentrate on the inflammatory stimulation and immunological modulation related with H. pylori infection.

Gastrin and CRC

Gastric atrophy produced by H. pylori-related gastritis results in hypergastrinemia following hypochlorhydria[47], and serum gastrin and H. pylori IgG are linked with an increased risk of CRC[48]. As a result, more research has focused on the relationship between gastrin and CRC, and it has been discovered that cholecystokinin B/gastrin receptors are over-expressed in CAP and CRC[49], and the gastrin binding capacity of CRC is ten times greater than that of normal colonic mucosa, promoting cell growth[50,51]. Furthermore, gastrin and progastrin have been shown to be released by CRC cells [52], and they operate as autocrine/paracrine growth factors to stimulate growth/anti-apoptosis in normal colonic mucosal cells, influencing gland development and shape[53,54]. Surprisingly, certain CRC cell proliferation may rely more on autocrine progastrin[55].

The role of gastrin in facilitating the advancement of the adenoma-carcinoma sequence in the colorectum has also received attention. Autocrine progastrin may activate Src kinase in CRC cells, hence mediating the proliferation/anti-apoptotic actions of endocrine/autocrine progastrin[56-58]. Furthermore, in vitro and in vivo research have revealed that the progastrin-related pathway may disturb normal stem cell populations by upregulating CD133, CD44, DCLK1, and Lgr5 stem cell markers, increasing cancer cells’ oncogenic and metastatic potential[56,59-61]. Progastrin also binds to the G protein-coupled receptor 56 in colon stem cells, conferring growth potential[62]. Furthermore, gastrin has been shown to upregulate many colon cancer target genes, including cyclin D1, vascular endothelial growth factor, vascular endothelial-cadherin, and matrix metalloproteinase-2, promoting tumor development[63-65]. Although different data point to the oncogenic qualities of gastrin and its derivatives, further study is required to determine the particular involvement of gastrin in the development of CRC.

1010 April 27, 2024 | Volume 16 | Issue 4
Changes in intestinal flora associated with \textit{H. pylori} infection

Environmental variables, such as food structure and intestinal flora, account for 80%-85% of CRC, and changes in intestinal microbial balance may function as environmental triggers for CRC\cite{66}. The quantity of intestinal flora varies with the origin and evolution of CRC\cite{67}. Simultaneously, increased abundance of pro-tumor bacteria such as polyketide synthase-positive (pkst+) \textit{Escherichia coli} (\textit{E. coli}), enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum can promote intestinal inflammation via toxins or metabolites, facilitate tumor cell proliferation and migration, and create an immunosuppressive microenvironment that limits anti-tumor immunity\cite{68,69}. The preceding data indicate that the intestinal flora plays an important role in the development of CRC and influences tumor chemotherapy and immunotherapy\cite{70}.

Chronic \textit{H. pylori} infection is a major cause of diminished microbial diversity in the stomach\cite{71}. It also boosts the number of microorganisms in stomach cancer, including nitrate-reducing bacteria, nitrosylbacteria, and \textit{E. coli}, which promotes nitrate metabolism. The resultant N-nitroso compounds function as carcinogens and promote tumorigenesis \cite{72}. An increasing body of evidence suggests that \textit{H. pylori} infection also impacts the intestinal flora. \textit{H. pylori} invasion of the intestinal mucosa may lead to reduced intestinal permeability\cite{72} and inhibit \textit{E. coli} DNA\cite{73}. \textit{H. pylori} may also trigger host immune responses, thereby altering the intestinal flora\cite{74,75}. Furthermore, long-term \textit{H. pylori} infection can alter the pH in the stomach, enabling more microorganisms to overcome the acid barrier and enter the distal intestinal tract\cite{75}. CagA also can stimulate the overproliferation of intestinal stem cells and alter the host microbiota\cite{76}. Recent study has revealed that \textit{H. pylori} promotes the enrichment of \textit{Akkermansia} spp. and \textit{Ruminococcus} spp., which breakdown intestinal mucus, in the colon tissue of \textit{H. pylori}-infected mice, resulting in a pro-inflammatory and pro-carcinogenic microbiota signature\cite{11}. It is possible that \textit{H. pylori} infection weakens the intestinal barrier. Furthermore, Luo et al\cite{77} discovered that in the early stages of CRC development, \textit{H. pylori} infection promotes the amplification of temperate phages to disrupt intestinal virome homeostasis and interacts with bacterial communities to target tumor-associated bacteria such as \textit{Lactobacillus}\cite{78} and \textit{Enterococcus faecalis}\cite{79}, promoting the development of CRC in mice. To summarize, \textit{H. pylori}-induced intestinal flora dysbiosis is a significant risk factor for the development of CRC.

The virulence factors of \textit{H. pylori}

\textit{H. pylori}'s virulence components, including as CagA, vacuolating cytotoxin A (VacA), and high-temperature requirement A, play a crucial role in the process by which \textit{H. pylori} causes stomach cancer. These virulence factors may increase the onset and development of gastric cancer by altering cell structure and shape, as well as impairing cell proliferation and apoptosis\cite{80}. Some investigations have shown that CagA expression\cite{81-83} and the serological response to \textit{H. pylori} VacA, particularly in African Americans\cite{30}, are related with an elevated risk of CRC formation. Furthermore, infection with robust strains of CagA-positive \textit{H. pylori} may contribute to the development of CRC by eliciting increased inflammatory responses\cite{84}. There is some indication that \textit{H. pylori} may be present in CPs\cite{85,86}, however further data is required to show the direct influence of \textit{H. pylori} bacterial components on the development of CRC. It cannot be ruled out that virulence factors like VacA may easily spread outside the stomach wall\cite{30,87}, thereby causing cancer.

\textbf{RISK FACTORS FOR H. PYLORI INFECTION}

A variety of variables impact \textit{H. pylori} infection rates, including economic position, living circumstances, cleanliness, lifestyle, occupation, and drinking water quality\cite{88}. It is also difficult for \textit{H. pylori} infections to resolve spontaneously\cite{89}. According to current research, \textit{H. pylori} infection rates are increased in obesity\cite{90}, portal hypertensive gastropathy\cite{91}, periodontal disease\cite{92}, and colon polyps\cite{93}. In addition, untreated dental caries may have an impact on systemic \textit{H. pylori} infection\cite{94}. Zhang et al\cite{42} hypothesized that age, BMI, and CAP were risk factors for \textit{H. pylori} infection after post-colon polyp surgery. Perhaps particular disorders can be utilized to identify those who are at high risk for \textit{H. pylori} infection.

\textbf{CONCLUSION}

In conclusion, Zhang et al\cite{42} performed a retrospective clinical study and discovered that age, BMI, and CAP were independent predictors of \textit{H. pylori} infection after postcolon polyp surgery. They also created a column-line graph prediction model with high calibration and predictive power for predicting the probability of \textit{H. pylori} infection. However, the \textit{H. pylori} prediction model may still be improved. Future studies should control for major confounding variables such as age, metabolic parameters, smoking, alcohol intake, physical activity, food, racial variations, socioeconomic level, and antibiotic usage. The investigation should also look into the association between the period of \textit{H. pylori} infection or recurrence following post-colon polyp surgery and CAP. Simultaneously, multi-center, large-scale prospective research should be carried out to create a scientifically rigorous \textit{H. pylori}-CRC screening program. More emphasis should be placed on the simultaneous diagnosis of CAP and \textit{H. pylori}-related disorders\cite{42,82,94} or specific diseases\cite{91}. This technique will not only increase the screening rate of those at high risk of \textit{H. pylori} infection and the diagnostic rate of infected individuals, but will also allow for a better understanding of the mechanism behind the link between \textit{H. pylori} infection and the development of CRC.
FOOTNOTES

Author contributions: Liu Y contributed to the writing, editing of the manuscript and table, and literature search; Yang DQ contributed to the discussion, design of the manuscript and literature search; Jiang JN contributed to the discussion and design of the manuscript; and Jiao Y designed the overall concept and outline of the manuscript.

Supported by the Health Science and Technology Capacity Improvement Project of Health Commission of Jilin Provincial, No. 2023JC016.

Conflict-of-interest statement: The authors have claimed no conflict of interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Yan Jiao 0000-0001-6914-7949.

S-Editor: Chen YL
L-Editor: A
P-Editor: Xu ZH

REFERENCES

cells in colorectal cancer.


polyp after endoscopic resection.

After Helicobacter pylori Eradication: A Retrospective Cohort Study.

Infection on Recurrence of Gastric Hyperplastic Polyp after Endoscopic Removal.

Colonic Adenomatous Polyps in Helicobacter pylori Infection.

Prospective Cohort Study.


Liu Y et al. H. pylori infection and CRC


Smith AM, Watson SA. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. *Gut* 2000; 47: 820-824 [PMID: 11076681 DOI: 10.1136/gut.47.6.820]


Adenomatous Polyps: a Cross-Sectional Study Based on 13,037 Cases of Gastrointestinal Endoscopy.


Romiopoulos I. Helicobacter pylori infection and colorectal carcinoma: pathologic aspects.


